JPWO2021067261A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021067261A5 JPWO2021067261A5 JP2022519458A JP2022519458A JPWO2021067261A5 JP WO2021067261 A5 JPWO2021067261 A5 JP WO2021067261A5 JP 2022519458 A JP2022519458 A JP 2022519458A JP 2022519458 A JP2022519458 A JP 2022519458A JP WO2021067261 A5 JPWO2021067261 A5 JP WO2021067261A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- conjugate
- cells
- pharmaceutical composition
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 102000002689 Toll-like receptor Human genes 0.000 claims description 21
- 108020000411 Toll-like receptor Proteins 0.000 claims description 21
- 230000003308 immunostimulating effect Effects 0.000 claims description 20
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 claims description 19
- 239000000556 agonist Substances 0.000 claims description 19
- 201000011510 cancer Diseases 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000003022 immunostimulating agent Substances 0.000 claims description 11
- 210000002865 immune cell Anatomy 0.000 claims description 9
- 229960001438 immunostimulant agent Drugs 0.000 claims description 8
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 claims description 8
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000007910 systemic administration Methods 0.000 claims description 6
- 108090000342 C-Type Lectins Proteins 0.000 claims description 4
- 102000003930 C-Type Lectins Human genes 0.000 claims description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 4
- 101000609473 Ecballium elaterium Trypsin inhibitor 2 Proteins 0.000 claims description 4
- 102000012064 NLR Proteins Human genes 0.000 claims description 4
- 108091005686 NOD-like receptors Proteins 0.000 claims description 4
- 108091005685 RIG-I-like receptors Proteins 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 claims description 4
- 229940124669 imidazoquinoline Drugs 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 101710164760 Chlorotoxin Proteins 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 102000053602 DNA Human genes 0.000 claims description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 2
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 101800003534 Kalata-B1 Proteins 0.000 claims description 2
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 2
- QPAKKWCQMHUHNI-GQIQPHNSSA-N chlorotoxin Chemical compound C([C@H]1C(=O)NCC(=O)N2CCC[C@H]2C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]4CSSC[C@@H](C(N[C@@H](CCSC)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)CNC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC2=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC4=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N3)=O)NC(=O)[C@@H](N)CCSC)C1=CC=C(O)C=C1 QPAKKWCQMHUHNI-GQIQPHNSSA-N 0.000 claims description 2
- 229960005534 chlorotoxin Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 230000001086 cytosolic effect Effects 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 102000007863 pattern recognition receptors Human genes 0.000 claims description 2
- 108010089193 pattern recognition receptors Proteins 0.000 claims description 2
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims description 2
- 108010026382 trypsin inhibitor MCoTI-II Proteins 0.000 claims description 2
- 108091058550 ω-conotoxin Proteins 0.000 claims description 2
- KNJNGVKTAFTUFL-OCMUWRIYSA-N ω-conotoxin Chemical compound N([C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1C(N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CO)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CSSC1)C(N)=O)=O)=O)C(=O)[C@@H]1CSSC[C@@H](N)C(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1 KNJNGVKTAFTUFL-OCMUWRIYSA-N 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 27
- 102000006495 integrins Human genes 0.000 description 14
- 108010044426 integrins Proteins 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 8
- 102000000844 Cell Surface Receptors Human genes 0.000 description 5
- 108010001857 Cell Surface Receptors Proteins 0.000 description 5
- 102000019997 adhesion receptor Human genes 0.000 description 5
- 108010013985 adhesion receptor Proteins 0.000 description 5
- 230000021164 cell adhesion Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000001268 conjugating effect Effects 0.000 description 4
- ZUHQCDZJPTXVCU-UHFFFAOYSA-N C1#CCCC2=CC=CC=C2C2=CC=CC=C21 Chemical compound C1#CCCC2=CC=CC=C2C2=CC=CC=C21 ZUHQCDZJPTXVCU-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- AUARUCAREKTRCL-BYPYZUCNSA-N [(4s)-4-amino-4-carboxybutyl]-diazonioazanide Chemical compound OC(=O)[C@@H](N)CCCN=[N+]=[N-] AUARUCAREKTRCL-BYPYZUCNSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025138126A JP2026004279A (ja) | 2019-09-30 | 2025-08-21 | ノッティン－免疫刺激剤複合体ならびに関連組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962908305P | 2019-09-30 | 2019-09-30 | |
| US62/908,305 | 2019-09-30 | ||
| PCT/US2020/053258 WO2021067261A1 (en) | 2019-09-30 | 2020-09-29 | Knottin-immunostimulant conjugates and related compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025138126A Division JP2026004279A (ja) | 2019-09-30 | 2025-08-21 | ノッティン－免疫刺激剤複合体ならびに関連組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022549915A JP2022549915A (ja) | 2022-11-29 |
| JPWO2021067261A5 true JPWO2021067261A5 (https=) | 2023-10-03 |
| JP2022549915A5 JP2022549915A5 (https=) | 2023-10-03 |
Family
ID=75337493
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022519458A Pending JP2022549915A (ja) | 2019-09-30 | 2020-09-29 | ノッティン－免疫刺激剤複合体ならびに関連組成物および方法 |
| JP2025138126A Pending JP2026004279A (ja) | 2019-09-30 | 2025-08-21 | ノッティン－免疫刺激剤複合体ならびに関連組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025138126A Pending JP2026004279A (ja) | 2019-09-30 | 2025-08-21 | ノッティン－免疫刺激剤複合体ならびに関連組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220257785A1 (https=) |
| EP (1) | EP4037709A4 (https=) |
| JP (2) | JP2022549915A (https=) |
| KR (1) | KR20220071225A (https=) |
| CN (1) | CN114585382A (https=) |
| AU (1) | AU2020357806A1 (https=) |
| CA (1) | CA3156165A1 (https=) |
| WO (1) | WO2021067261A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| EP3774986A1 (en) | 2018-04-13 | 2021-02-17 | Massachusetts Institute of Technology | Brush prodrugs and uses thereof |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| CN113891731A (zh) * | 2019-05-22 | 2022-01-04 | 小利兰·斯坦福大学理事会 | 药物缀合物及其使用方法 |
| KR20220085791A (ko) * | 2019-10-16 | 2022-06-22 | 메사추세츠 인스티튜트 오브 테크놀로지 | 브러시 전구약물 및 그의 용도 |
| WO2025103490A1 (en) * | 2023-11-16 | 2025-05-22 | Beijing Changping Laboratory | N-oxide immune agonists activation by radiotherapy |
| WO2025193946A2 (en) * | 2024-03-14 | 2025-09-18 | Genentech, Inc. | Peptides binding lrrc15 and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2638173B1 (en) * | 2010-11-08 | 2019-06-19 | The Board of Trustees of The Leland Stanford Junior University | Fusion proteins comprising an engineered knottin peptide and uses thereof |
| WO2014063012A1 (en) * | 2012-10-19 | 2014-04-24 | The Board Of Trustees Of The Leland Stanford Junior University | Conjugated knottin mini-proteins containing non-natural amino acids |
| WO2014201245A1 (en) * | 2013-06-12 | 2014-12-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors |
| JP6800141B2 (ja) * | 2014-08-12 | 2020-12-16 | マサチューセッツ インスティテュート オブ テクノロジー | Ｉｌ−２およびインテグリン結合性ｆｃ融合タンパク質による相乗的な腫瘍処置 |
| US10888603B2 (en) * | 2016-02-12 | 2021-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cancer cells expressing tumor-associated integrins |
| US10765625B2 (en) * | 2016-03-15 | 2020-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | Knottin-drug conjugates and methods of using the same |
| MX2019012295A (es) * | 2017-04-14 | 2020-02-07 | Tollnine Inc | Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso. |
| CN113891731A (zh) * | 2019-05-22 | 2022-01-04 | 小利兰·斯坦福大学理事会 | 药物缀合物及其使用方法 |
| US20230211001A1 (en) * | 2020-07-30 | 2023-07-06 | The Board Of Trustees Of The Leland Stanford Junior University | Lysosomal Targeting Molecules Comprising Knottin Peptides And Related Compositions And Methods |
-
2020
- 2020-09-29 CA CA3156165A patent/CA3156165A1/en active Pending
- 2020-09-29 JP JP2022519458A patent/JP2022549915A/ja active Pending
- 2020-09-29 AU AU2020357806A patent/AU2020357806A1/en active Pending
- 2020-09-29 CN CN202080072773.4A patent/CN114585382A/zh active Pending
- 2020-09-29 US US17/762,694 patent/US20220257785A1/en active Pending
- 2020-09-29 EP EP20870659.8A patent/EP4037709A4/en active Pending
- 2020-09-29 KR KR1020227013406A patent/KR20220071225A/ko active Pending
- 2020-09-29 WO PCT/US2020/053258 patent/WO2021067261A1/en not_active Ceased
-
2025
- 2025-08-21 JP JP2025138126A patent/JP2026004279A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114502191B (zh) | 通过施用具有关联的抗原的聚合物囊泡群和具有关联的佐剂的聚合物囊泡群来引发免疫应答的方法以及包含这两种聚合物囊泡群的组合物 | |
| US12370258B2 (en) | PD-1 and CTLA-4 dual inhibitor peptides | |
| US7740882B2 (en) | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents | |
| KR20240149976A (ko) | 펩티드-기반 백신, 그의 제조 방법, 및 면역 반응을 유도하기 위한 그의 용도 | |
| US20060051315A1 (en) | Polymers for delivering peptides and small molecules in vivo | |
| WO2001091798A2 (en) | Tumor activated prodrug compounds | |
| AU2019272844B2 (en) | Improved methods of manufacturing peptide-based vaccines | |
| US20220395554A1 (en) | LAG3 Binding Peptides | |
| CN103417480A (zh) | 一种靶向整合素受体的新型多肽修饰的肿瘤靶向脂质体 | |
| CN115551555A (zh) | 用于修饰car-t细胞活性的方法、化合物和组合物 | |
| CN112048002A (zh) | 一种靶向t细胞的酶敏感纳米体系及其制备方法和应用 | |
| Liu et al. | Dendritic cell targeting peptide-based nanovaccines for enhanced cancer immunotherapy | |
| Kelly et al. | Titrating polyarginine into nanofibers enhances cyclic-dinucleotide adjuvanticity in vitro and after sublingual immunization | |
| US11338040B2 (en) | Immunomodulatory compounds | |
| JPWO2021067261A5 (https=) | ||
| Sowndharya et al. | Self-adjuvanting adenoviral nanovaccine for effective T-cell-mediated immunity and long-lasting memory cell activation against tuberculosis | |
| WO2022026496A2 (en) | Lag3 binding peptides | |
| JP2022550901A (ja) | 核酸治療薬のための腫瘍標的化ポリペプチドナノ粒子送達システム | |
| JP2024500360A (ja) | 関連づけられた抗原および関連づけられたアジュバントを有する２つのポリマーソーム集団を投与することによる、Ｔｈ１／Ｔｈ２免疫応答の調整方法 | |
| CN120424167A (zh) | 双功能化合物及其在蛋白质靶向降解中的应用 | |
| CA2408103A1 (en) | Tumor activated prodrug compounds and methods of making and using the same | |
| US20260091097A1 (en) | Combination treatment regimes for treating cancer | |
| Zhao et al. | Mechanisms of Engineered Cell Membrane Technology and Its Applications in Tumor and Non-Tumor Diseases | |
| Sun | Protein Engineering Approaches towards Respiratory Disease Prevention and Therapeutics: From Lung Cancer to COVID-19 |